key: cord-0951964-7itvbvgq authors: Siami, Zeinab; Aghajanian, Sepehr; Mansouri, Somayeh; Mokhames, Zakiye; Pakzad, Reza; Kabir, Kourosh; Norouzi, Mehdi; Soleimani, Alireza; Yaghoobi, Mojtaba Hedayat; Shadabi, Shahrzad; Tajbakhsh, Ramin; Khairabad, Ali Kargar; Mozhgani, Sayed-Hamidreza title: Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial date: 2021-04-18 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.04.043 sha: 4bbf344bc3cdeb7f14602c3d4df53ff41455b4bb doc_id: 951964 cord_uid: 7itvbvgq Objective The COVID-19 pandemic has called an urgent need for drug repurposing to improve the outcome of the disease. Quaternary ammonium compounds have been demonstrated to have antiviral effects and may be of use against SARS-CoV-2 infections. Design In this double-blind, single-center study, we enrolled patients with positive PCR test and/or CT findings for COVID-19. The participants of each group were randomly assigned to Diphenhydramine Compound (Diphenhydramine + Ammonium Chloride) plus standard of care or to Diphenhydramine alone and standard of care groups. The primary outcome was all-cause mortality within 30 days of randomization. Secondary outcomes include viral burden, clinical status, assessed by a 5-point ordinal scale, and length of stay in hospitalized patients. Results A total of 120 patients were included in the trial, 60 of which were assigned to Ammonium Chloride group. The primary endpoint was not statistically different between the two groups (HR: 3.02 (95% CI, 0.57-16.06; p = 0.195)). Recovery time and viral burden was significantly lower in Ammonium Chloride group corresponding to odds ratios of 1.8 (95% CI, 1.15-2.83; p = 0.01) and 7.90 (95% CI, 1.62-14.17; p = 0.014), respectively. Conclusion The findings of this advocates the careful addition of Ammonium Chloride to standard of care for COVID-19 patients. Zeinab Siami 1 , Sepehr Aghajanian 2 , Somayeh Mansouri 2 , Zakiye Mokhames 3 The baseline data was acquired using paper-based questionnaires that included symptoms upon admission, history of illnesses, major coexisting illnesses, and demographic data. Using a four-unit permuted block randomization, the patients were assigned (1:1) to either Diphenhydramine and Ammonium Chloride (10ml oral syrup three times a day for 7 days) plus standard of care or Diphenhydramine (10ml oral syrup three times a day for 7 days) plus standard of care alone. For double blinding, the Medicine box were either labeled as A (Ammonium Chloride) or B (Control). At the time of the trial, Diphenhydramine was part of the standard care in outpatients and hospitalized COVID-19 patients to provide symptomatic alleviation of the disease in this hospital. Therefore, we opted to use already formulated Diphenhydramine compound (12.5 mg Diphenhydramine + 125 mg Ammonium Chloride / 5ml syrup) for our intervention group and Diphenhydramine (12.5 mg Diphenhydramine / 5 ml syrup) as placebo for control group. The standard of care in the hospital also included concomitant Atazanavir (300 mg PO bid in hospitalized patients) and Methylprednisolone (1g/day for 3 days in patients admitted to ICU) based on hospital recommendations. Laboratory tests were obtained following admission into hospital. HRCT-scan imaging and RT-PCR tests were performed on the day of admission as baseline measurements and a second assessment was performed at day 7 after randomization to evaluate clinical improvements. The primary outcome was all-cause mortality within 30 days after randomization for all patients. The secondary outcomes included hospitalization duration in discharged patients, clinical status at day 7 following randomization and viral burden. The scores on the ordinal clinical status scale is fully demonstrated in Table 1 . The study sample size for each treatment arm was calculated to be 60, in order for the trial to have 80% power at a two-sided P value of 0.05 to detect a clinically relevant reduction in mortality with an assumed mortality rate of 10.9% and 2% in intervention and control group (5). The statistical plan and analysis of all outcomes and the effect of Ammonium Chloride on CT findings and ICU admission and the use of invasive mechanical ventilation as standalone endpoints have been described in Table 2 . Between August 22 and October 22, 2020, 120 patients were included in the trial, with 60 patients receiving Ammonium Chloride. 45 patients in Ammonium Chloride and 44 patients in control group comprised the hospitalized patients, respectively. Baseline characteristics of the participants is available in Supplementary Table 1 . The Kaplan-Meier curve for the time to death as primary end-point is shown in Supplementary The findings of this trial suggest that the addition of Ammonium Chloride to standard of care was not superior to standard of care alone in reducing mortality rate in COVID-19 patients. Patients receiving Ammonium Chloride had shorter time to recovery and were more likely to have reduced viral load and clinical improvement. This trial was funded and made possible by the grant provided by Alborz University of Medical Sciences (Grant Number: 3762-6). The trial was approved by ethics committee at Alborz University of Medical Sciences (Approval No. 3762-6). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J o u r n a l P r e -p r o o f The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control Ammonium Chloride as a Potential Candidate for the Treatment and Controlling of Covid-19. virusj Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19 Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.